Navigation Links
Intercept Pharmaceuticals Raises $25 Million Series B Financing
Date:1/25/2010

NEW YORK, Jan. 25 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the completion of a $25 million Preferred Series B financing by its majority shareholder Genextra S.p.A.

Dr. Mark Pruzanski, founder, President and CEO commented, "This financing is recognition of the success we have had advancing our lead compounds INT-747 and INT-777. Genextra's strong backing will enable us to advance our clinical programs while continuing to build our pipeline of novel small molecules targeting FXR, TGR5 and other bile acid receptors."

In conjunction with the financing, Dr. Lorenzo Tallarigo, CEO of Genextra and Intercept director, is assuming the role of Chairman. Dr. Tallarigo stated, "This financing adds substantially to Genextra's investment in Intercept. With two positive Phase II studies last year, the company has made great progress in validating the therapeutic utility of INT-747 and the novel class of compounds it belongs to more broadly."

About Intercept Pharmaceuticals

Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Bile acid signaling through these receptors regulates key aspects of lipid, glucose and overall energy metabolism, while also serving to maintain the functional integrity of the liver, intestine and kidney, organs that are exposed to bile acid flux.

About INT-747 (first-in-class FXR agonist)

INT-747 is a potent, first-in-class farnesoid X receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid (CDCA), the natural endogenous FXR agonist.  In 2009, the company announced positive Phase II results for INT-747 in refractory primary biliary cirrhosis (PBC) patients, as well as in type 2 diabetics with nonalcoholic fatty liver disease. These data support INT-747's potential as a novel hepatoprotective therapeutic across a range of chronic liver diseases. Intercept is currently preparing for an End of Phase II meeting with FDA to determine a Phase III program for PBC.

About INT-777 (TGR5 agonist)

INT-777, a modified human bile acid, is a potent TGR5 agonist that induces the release of GLP-1 in the gut and normalizes glucose tolerance in obese, insulin resistant (DIO) and diabetic (db/db) mice.  INT-777 also prevents weight gain and fat accumulation in mice on a high fat diet by increasing energy expenditure and fat burning; while preserving liver function by reducing steatosis and fibrosis.  Intercept intends to file an IND for INT-777 in the third quarter of 2010.

For more information about Intercept, please go to www.interceptpharma.com; for information about Genextra, please go to www.genextra.it. CONTACT: Mark Pruzanski, M.D., or Barbara Duncan, both of Intercept Pharmaceuticals at +1.646.747.1000; Paolo Fundaro of Genextra at +39.02.365.15114

SOURCE Intercept Pharmaceuticals, Inc.

RELATED LINKS
http://www.interceptpharma.com

'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
2. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
3. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
4. Amylin Pharmaceuticals to Webcast Year-End Financial Results
5. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
6. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
7. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
8. Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms
9. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
10. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
11. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)...  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas ...
(Date:6/23/2016)... June 23, 2016  Experian Health, the ... transforming the patient payment and care experience, ... new products and services that will enhance ... cycle offerings. These award-winning solutions will enable ... remain compliant in an ever-changing environment and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):